▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2312 by analyst upside · 2026-11-13
RYTM
Rhythm Pharmaceuticals, Inc.
Healthcare · Market Cap $8B · P/E 0x
ANALYST PRICE TARGET
+27.5%
implied upside to consensus target
Current Price $109.86
Consensus Target $140.12
Bull Target $168.0
Bear Target $112.0
Analysts Covering 17
ANALYST CONSENSUS - BUY
Strong Buy
4
Buy
11
Hold
2
Sell
0
52-Week Low $74.5
52-Week High $122.2
YTD Return +4.6%
FUNDAMENTALS
Market Cap $8B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-2.91
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $281M
Profit Margin -69.0%
52-WEEK RANGE
52-Week Low $74.5
52-Week High $122.2
Current Price $109.86
Bear Target $112.0
Bull Target $168.0
● Now $109.86 ● Target $140.12
TRADING DATA
Avg Volume 991K
YTD Return +4.6%
Analyst Count 17
Consensus Buy
Upside to Target +27.5%
Last Updated 2026-11-13

ANALYST SUMMARY

Rhythm Pharmaceuticals, Inc. (RYTM) is currently trading at $109.86 with a Wall Street consensus price target of $140.12, implying potential upside of 27.5% over the next 12 months. 17 analysts currently cover RYTM, with a consensus rating of Buy - 88% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $168.0, while the most cautious has a target of $112.0.

RYTM operates in the Healthcare sector with a market capitalisation of $8B. The stock is up 4.6% year-to-date and is currently trading near the upper end of its 52-week range of $74.5 – $122.2.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for RYTM, with each firm's 90-day track record across all stocks we track. See full firm rankings →

JP Morgan - Reiterated
Overweight → Overweight 2026-11-07 43% win rate (7 calls)
Guggenheim - Reiterated
Buy → Buy 2026-11-05 62% win rate (8 calls)
Citizens - Reiterated
Market Outperform → Market Outperform 2026-11-04 Building track record
Needham - Reiterated
Buy → Buy 2026-11-03 20% win rate (5 calls)
William Blair ● Initiated
Outperform 2026-10-16 44% win rate (9 calls)
JP Morgan - Reiterated
Overweight → Overweight 2026-10-15 43% win rate (7 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-10-12 31% win rate (48 calls)
RBC Capital - Reiterated
Outperform → Outperform 2026-10-08 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
64
out of 100
Coverage depth
22/30
Consensus clarity
20/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →